Joint (NASDAQ:JYNT) Announces Earnings Results

Key Points

• Joint met earnings expectations with quarterly EPS of $0.05 and exceeded revenue estimates, reporting $15.18 million versus the $14.57 million consensus.
• Profitability and cash flow improved sharply: Revenue rose 14% to $15.2 million, adjusted EBITDA reached $1.5 million, and free cash flow increased to $1.9 million. Refranchising is also nearing completion, supporting a more capital-light business model.
• Growth remains challenging: System-wide sales fell 3.7% year over year, comparable sales declined 2.8%, and the 2026 new-clinic opening outlook was reduced to 22–26 from 30–35, although full-year EBITDA guidance was maintained.

Joint (NASDAQ:JYNT - Get Free Report) posted its quarterly earnings data on Thursday. The company reported $0.05 earnings per share for the quarter, meeting analysts' consensus estimates of $0.05, FiscalAI reports. The firm had revenue of $15.18 million for the quarter, compared to analysts' expectations of $14.57 million. Joint had a return on equity of 11.70% and a net margin of 6.49%.

Here are the key takeaways from Joint's conference call:

• Profitability and cash flow improved sharply: Q2 revenue rose 14% to $15.2 million, Adjusted EBITDA from continuing operations increased to $1.5 million from $88,000, and free cash flow grew $1.6 million to $1.9 million.
• Refranchising is nearing completion, with clinic ownership transfers and management service agreements progressing across the three sale bundles. Once finalized, The Joint expects to have only three remaining company-owned or managed clinics, supporting a more capital-light model.
• Patient retention reached its best level in more than five years following the rollout of flexible membership options, while active-member trends improved sequentially. Management also reported no meaningful patient pushback to price increases implemented at more than 500 clinics.
• System-wide sales declined 3.7% year over year and Q2 comparable sales were negative 2.8%, although management said July and second-half trends were improving.
• The company reduced its 2026 new-clinic opening outlook to 22–26 from 30–35, and expects year-end clinic count to be below 2025 levels as closures and portfolio optimization offset new openings. Full-year guidance was otherwise reiterated, including $12.5 million–$13.5 million of consolidated Adjusted EBITDA.

Joint Trading Up 1.3%

Shares of NASDAQ:JYNT traded up $0.11 during trading on Friday, reaching $8.33. The company's stock had a trading volume of 104,765 shares, compared to its average volume of 60,308. The stock has a market capitalization of $118.79 million, a PE ratio of 30.85 and a beta of 1.10. Joint has a 12 month low of $7.50 and a 12 month high of $11.26. The firm's 50 day simple moving average is $8.76 and its two-hundred day simple moving average is $8.87.

Wall Street Analyst Weigh In

A number of research firms have commented on JYNT. Weiss Ratings upgraded shares of Joint from a "sell (d+)" rating to a "hold (c-)" rating in a research note on Friday, June 12th. Wall Street Zen upgraded shares of Joint from a "buy" rating to a "strong-buy" rating in a research report on Saturday. Finally, Zacks Research lowered Joint from a "strong-buy" rating to a "hold" rating in a research note on Tuesday, July 7th. Three investment analysts have rated the stock with a Hold rating, Based on data from MarketBeat, the company presently has an average rating of "Hold".

Insider Transactions at Joint

In other news, major shareholder Charles E. Jobson acquired 127,676 shares of the company's stock in a transaction on Tuesday, May 12th. The stock was bought at an average cost of $8.57 per share, with a total value of $1,094,183.32. Following the completion of the purchase, the insider directly owned 1,773,479 shares of the company's stock, valued at $15,198,715.03. This represents a 7.76% increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. 30.20% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Joint

Large investors have recently made changes to their positions in the company. BNP Paribas Financial Markets grew its holdings in Joint by 104.7% during the 3rd quarter. BNP Paribas Financial Markets now owns 2,935 shares of the company's stock valued at $28,000 after purchasing an additional 1,501 shares during the last quarter. JPMorgan Chase & Co. lifted its stake in Joint by 32.3% in the second quarter. JPMorgan Chase & Co. now owns 7,412 shares of the company's stock worth $86,000 after purchasing an additional 1,810 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its position in shares of Joint by 25.9% during the second quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 8,244 shares of the company's stock valued at $95,000 after buying an additional 1,698 shares during the period. XTX Topco Ltd purchased a new position in shares of Joint during the fourth quarter valued at approximately $124,000. Finally, Wells Fargo & Company MN grew its stake in shares of Joint by 78.0% during the fourth quarter. Wells Fargo & Company MN now owns 15,476 shares of the company's stock valued at $135,000 after buying an additional 6,784 shares during the last quarter. 76.88% of the stock is owned by hedge funds and other institutional investors.

Joint Company Profile

The Joint Chiropractic, Inc, doing business as Joint NASDAQ: JYNT, is a franchisor and operator of outpatient chiropractic clinics in the United States. Under its flagship The Joint Chiropractic brand, the company offers membership-based, cash-focused spinal adjustment services designed to promote accessible, routine care for neck and back discomfort. By removing insurance requirements and offering walk-in visits, Joint aims to streamline the patient experience and reduce cost barriers to ongoing chiropractic treatment.

Joint's growth strategy centers on partnering with franchisees to expand its network of clinics.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source